Financing Cash Flow
Regeneron Pharmaceuticals Financing Cash Flow decreased by 2.8% to -$802.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.3%, from -$1.09B to -$802.20M. Over 4 years (FY 2021 to FY 2025), Financing Cash Flow shows a downward trend with a 38.6% CAGR.
Analysis
How to read this metric
A large negative value typically indicates a company is returning capital to shareholders or paying down debt, while a positive value suggests the company is raising external capital to fund operations or acquisitions.
Detailed definition
This metric represents the net flow of cash between a company and its capital providers, including shareholders and lend...
Peer comparison
Large-cap peers like Microsoft or Alphabet similarly show large negative financing outflows due to aggressive share repurchase programs and dividend distributions.
net_cash_from_financingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$118.20M | $385.40M | -$906.60M | $64.70M | -$101.10M | -$725.00M | -$247.60M | -$322.50M | -$614.20M | -$407.30M | -$446.10M | $47.10M | -$478.10M | -$634.00M | -$1.14B | -$1.09B | -$1.13B | -$717.90M | -$780.10M | -$802.20M |
| QoQ Change | — | +426.1% | -335.2% | +107.1% | -256.3% | -617.1% | +65.8% | -30.3% | -90.4% | +33.7% | -9.5% | +110.6% | <-999% | -32.6% | -79.1% | +4.1% | -3.6% | +36.4% | -8.7% | -2.8% |
| YoY Change | — | — | — | — | +14.5% | -288.1% | +72.7% | -598.5% | -507.5% | +43.8% | -80.2% | +114.6% | +22.2% | -55.7% | -154.5% | <-999% | -136.0% | -13.2% | +31.3% | +26.3% |
Financing Cash Flow at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's financing cash flow?
- Regeneron Pharmaceuticals (REGN) reported financing cash flow of -$802.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's financing cash flow changed year-over-year?
- Regeneron Pharmaceuticals's financing cash flow increased by 26.3% year-over-year, from -$1.09B to -$802.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's financing cash flow?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's financing cash flow has grown at a 38.6% compound annual growth rate (CAGR), from -$1.01B to -$3.72B.
- What does financing cash flow mean?
- The total amount of money a company spends or receives from borrowing debt and managing its own shares and dividends.